Natural plasma inhibitors in individuals with high risk for thrombotic disease
Engel, A.M.
Thrombosis and Haemostasis 38(1): 248
1977
ISSN/ISBN: 0340-6245
Accession: 027012645
PDF emailed within 1 workday: $29.90
Related References
Lind, L.; Ingelsson, E.; Ärnlöv, J.; Sundström, J.; Zethelius, B.ör.; Reaven, G.M. 2018: Can the Plasma Concentration Ratio of Triglyceride/High-Density Lipoprotein Cholesterol Identify Individuals at High Risk of Cardiovascular Disease During 40-Year Follow-Up? Metabolic Syndrome and Related Disorders 16(8): 433-439Mousavi, Z.; Soleymani, S.; Hassanshahi, G.; Nikbakht, R.; Mirzaee Khalilabadi, R. 2020: Low levels of coagulation inhibitors: a high-risk thrombotic factor in thalassemic patients Revista Clinica Espanola 220(3): 162-166
Mclaughlin, T.; Abbasi, F.; Lamendola, C.; Reaven, G. 2003: Use of plasma triglyceride/high density cholesterol ratio to identify insulin resistant individuals at risk for cardiovascular disease and type 2 diabetes Diabetes 52(Suppl 1): A224
Dandoy, C.E.; Stegman, A.; Pate, A.R.; Stendahl, A.; Alonso, P.B.; Jodele, S.; Lane, A.; Davies, S.M. 2019: Thrombotic Microangiopathy after Pediatric Allogeneic Stem Cell Transplant: Potential Early Markers to Predict Individuals at High-Risk Biology of Blood and Marrow Transplantation 25(3): S45-S46
Bagaglio, S.; Messina, E.; Hasson, H.; Merli, M.; Lazzarin, A.; Smacchia, A.; Uberti-Foppa, C.; Morsica, G. 2014: P1240 Characterization of Hcv-1 Subtypes and Natural Resistance to Protease Inhibitors in Liver and Plasma Compartments of Hiv/Hcv Coinfected Individuals Journal of Hepatology 60(1): S502-S503
Morser, M.J.; Nagashima, M. 1999: Method of detecting thrombotic disease risk associated with plasma carboxypeptidase B polymorphisms Official Gazette of the United States Patent and Trademark Office Patents 1228(3)
Winsløw, U.C.; Nordestgaard, B.G.; Afzal, S. 2018: High plasma 25-hydroxyvitamin D and high risk of nonmelanoma skin cancer: a Mendelian randomization study of 97 849 individuals British Journal of Dermatology 178(6): 1388-1395
Pabinger, I.; Schneider, B. 1994: Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. the GTH Study Group on Natural Inhibitors Thrombosis and Haemostasis 71(5): 548-552
Price, H.C.; Tucker, L.; Griffin, S.J.; Holman, R.R. 2008: The impact of individualised cardiovascular disease (CVD) risk estimates and lifestyle advice on physical activity in individuals at high risk of CVD: a pilot 2 x 2 factorial understanding risk trial Cardiovascular Diabetology 7: 21
Teofili, L.; De Stefano, V.; Iovino, M.S.; Bizzi, B.; Leone, G. 1992: An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression Cancer 70(6): 1647-8; author reply 1648-9
Barosi, G.; Buratti, A.; Costa, A.; Liberato, L.N.; Balduini, C.; Cazzola, M.; Rosti, V.; Magrini, U.; Ascari, E. 1991: An atypical myeloproliferative disorder with high thrombotic risk and slow disease progression Cancer 68(10): 2310-2318
Al-Rousan, N.; Al-Najjar, H. 2020: Data analysis of coronavirus COVID-19 epidemic in South Korea based on recovered and death cases Journal of medical virology 92(9): 1603-1608
Stain, M.; Schönauer, V.; Minar, E.; Bialonczyk, C.; Hirschl, M.; Weltermann, A.; Kyrle, P.A.; Eichinger, S. 2005: The post-thrombotic syndrome: risk factors and impact on the course of thrombotic disease Journal of Thrombosis and Haemostasis: Jth 3(12): 2671-2676
Pabinger, I.; Schneider, B. 1996: Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose- und Hamostaseforschung (GTH) Study Group on Natural Inhibitors Arteriosclerosis Thrombosis and Vascular Biology 16(6): 742-748
Schechter, M.; Struchiner, C.J.; Harrison, L.H. 1999: Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV disease progression: is more necessarily better? Aids 13(1): 97-102